Following intravenous injection of [F-18]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed and viewed on a MIMVista or similar workstation. The uptake pattern of [F-18]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.
This study will look at how [18F]MHF goes into normal knee replacements and those with suspected infection.

Start Date01 Sep 2024

Sponsor / Collaborator

Emory University

[+1]

100 Clinical Results associated with Fluorine-18 Maltodextrin

100 Translational Medicine associated with Fluorine-18 Maltodextrin

100 Patents (Medical) associated with Fluorine-18 Maltodextrin

192

Literatures (Medical) associated with Fluorine-18 Maltodextrin

08 Nov 2024·ACS Infectious Diseases

Preclinical Positron Emission Tomography (PET) of Prosthetic Joint Infection Using a Nitro-Prodrug of 2-[¹⁸F]F-p-Aminobenzoic Acid ([¹⁸F]F-PABA)

Article

Author: Li, Yong ; Meimetis, Labros ; Tonge, Peter J. ; Qu, Wenchao ; Ahn, Shin Hye ; Bravo, Eduardo ; Schlyer, David J. ; Wang, Mingqian ; Pollard-Kerning, Alyssa C. ; Komatsu, David E. ; Akoglu, Melike ; Akula, Hari K. ; DelloRusso, Francesca ; Li, Kaixuan

Deep-seated bacterial infections are difficult to detect and diagnose due to the lack of specific clinical imaging modalities. Therefore, the bacteria-specific positron emission tomography radiotracer 2-[¹⁸F]fluoro-4-nitrobenzoic acid ([¹⁸F]FNB) was developed, which is reduced to 2-[¹⁸F]fluoro-4-aminobenzoic acid ([¹⁸F]F-PABA) by bacterial nitroreductases and has improved pharmacokinetics compared to the parent compound. PET imaging demonstrated that the uptake of 2-[¹⁸F]fluoro-4-nitrobenzoic acid in a clinically relevant Staphylococcus aureus prosthetic joint infection model was up to ∼4-fold higher in the infected joint compared to the contralateral joint. 2-[¹⁸F]Fluoro-4-nitrobenzoic acid was also able to distinguish infection from inflammation in a surgical inflammation model. Based on the mouse radiation dosimetry results, the calculated effective dose of 2-[¹⁸F]fluoro-4-nitrobenzoic acid was well below the whole-body radiation dose limit established by the Food and Drug Administration for humans. In addition, no treatment-related microscopic changes in organ histopathology were observed in a mouse acute toxicity study. Overall, these data suggest that 2-[¹⁸F]fluoro-4-nitrobenzoic acid is a specific and effective imaging agent for noninvasively diagnosing prosthetic joint infections.

01 Sep 2024·European Journal of Nuclear Medicine and Molecular Imaging

Diagnostic efficacy of [68Ga]Ga-DOTA-GPFAPI-04 in patients with solid tumors in a head-to-head comparison with [18F]F-FDG: results from a prospective clinical study

Article

Author: Shang, Yuxiang ; Zhang, Guojin ; Zhang, Qing ; Jiang, Lei ; Liu, Entao ; Lai, Chaoquan ; Cheng, Zhen ; Yuan, Hui

PURPOSETo identify the biodistribution and diagnostic performance of a novel fibroblast activation protein (FAP) targeted positron emission tomography (PET) tracer, [⁶⁸Ga]Ga-DOTA-GPFAPI-04, in patients with solid tumors in a head-to-head comparison with [¹⁸F]F-FDG.METHODSTwenty-six patients histologically proven with cancers of nasopharyngeal (n = 5), esophagus (n = 5), gastro-esophagus (n = 1), stomach (n = 7), liver (n = 3), and colorectum (n = 5) were recruited for [⁶⁸Ga]Ga-DOTA-GPFAPI-04 and [¹⁸F]F-FDG PET/CT scans on consecutive days. The primary endpoint was the diagnostic efficacy, with the histological diagnosis and the follow-up results selected as the gold standard. The secondary endpoint was the background uptake pattern. Two experienced nuclear medicine physicians who were blinded to the gold standard results while having essential awareness of the clinical context reviewed the images and labeled lesions by consensus for subsequent software-assisted lesion segmentation. Additionally, background organs were automatically segmented, assisted by artificial intelligence. Volume, mean, and maximum standard uptake values (SUVmean and SUVmax) of all segmentations were recorded. P < 0.05 was deemed as statistically significant.RESULTSSignificant glandular uptake of [⁶⁸Ga]Ga-DOTA-GPFAPI-04 was detected in the thyroid, pancreas, and submandibular glands, while moderate uptake was observed in the parotid glands. The myocardium and myometrium exhibited 2-3 times higher uptake of the radiotracer than that of the background levels in blood and liver. A total of 349 targeted lesions, consisting of 324 malignancies and 25 benign lesions, were segmented. [⁶⁸Ga]Ga-DOTA-GPFAPI-04 is more sensitive than [¹⁸F]F-FDG, especially for abdominopelvic dissemination (1.000 vs. 0.475, P < 0.001). Interestingly, [¹⁸F]F-FDG demonstrated higher sensitivity for lung metastasis compared to [⁶⁸Ga]Ga-DOTA-GPFAPI-04 (0.845 vs. 0.682, P = 0.003). The high glandular uptake made it difficult to delineate lesions in close proximity and masked two metastatic lesions in these organs.CONCLUSIONDespite prominent glandular uptake, [⁶⁸Ga]Ga-DOTA-GPFAPI-04 demonstrates favorable diagnostic performance. It is a promising probe scaffold for further development of FAP-targeted tumor theranostic agents.

26 Aug 2024·JACS Au

¹⁸F-Fluorination of Nitroimidazolyl-Containing Sultone: A Direct Access to a Highly Hydrophilic Radiotracer for High-Performance Positron Emission Tomography Imaging of Hypoxia

Article

Author: Cao Pham, Thanh T. ; Maingueneau, Clémence ; Perrio, Cécile ; Guillouet, Stéphane ; Lafargue, Anne-Elodie ; Fillesoye, Fabien ; Jordan, Bénédicte F.

Hypoxia, characterized by nonphysiological levels of oxygen tension, is a key phenomenon common to the majority of malignant tumors with poor prognosis. Many efforts have been made to develop hypoxia imaging for diagnosis, staging, and monitoring of diseases, as well as for evaluating therapies. PET Imaging using ¹⁸F-fluoronitroimidazoles (i.e., [¹⁸F]FMISO as a lead radiotracer) has demonstrated potential for clinical investigations, but the poor contrast and prolonged acquisition times (>2.5 h) strongly limit its accuracy and routine developments. Here, we report an original [¹⁸F]fluoronitroimidazole bearing a sulfo group ([¹⁸F]FLUSONIM) that displays highly hydrophilic properties and rapid clearance, providing high-performance hypoxia specific PET imaging. We describe the synthesis and radiosynthesis of [¹⁸F]FLUSONIM, its in vivo preclinical evaluation by PET imaging in healthy rats and a rhabdomyosarcoma rat model, as well as its radiometabolization and histological studies. [¹⁸F]FLUSONIM was prepared in a single step by high yielding radiofluorination of a sultone precursor, highlighting the advantages of this new radiolabeling approach not yet explored for radiopharmaceutical development. PET imaging experiments were conducted by systematically comparing [¹⁸F]FLUSONIM to [¹⁸F]FMISO as a reference. The overall results unequivocally demonstrate that the developed radiopharmaceutical meets the criteria of an ideal candidate for hypoxia PET imaging-rapid and efficient radiosynthesis, total stability, exclusive urinary elimination, high specificity for hypoxic regions, unprecedented tumor/background ratios, short acquisition delays (<60 min), and promising potential for further preclinical and clinical applications.

100 Deals associated with Fluorine-18 Maltodextrin

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
complications; implant, orthopedic	Phase 2	US	Emory University	01 Sep 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Fluorine-18 Maltodextrin

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation